Effect of recombinant Lactococcus lactis producing myelin peptides on neuroimmunological changes in rats with experimental allergic encephalomyelitis

Folia Neuropathologica

Volumn 54, Issue 3, 2016, Pages 249-258

  Kasarełło, Kaja ^a,b   Szczepankowska, Agnieszka ^c   Kwiatkowska Patzer, Barbara ^b   Lipkowski, Andrzej W ^b   Gadamski, Roman ^d   Sulejczak, Dorota ^d   Łachwa, Magdalena ^d   Biały, Michał ^a   Bardowski, Jacek ^c  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

^c INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

^d MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Autoimmunity; EAE; Lactococcus lactis; MS; Myelin proteins; Oral tolerance

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROTEOLIPID PROTEIN; TUMOR NECROSIS FACTOR; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; CELL LYSATE; CONTROLLED STUDY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; LACTOCOCCUS LACTIS; MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SPINAL CORD; ANIMAL; DISEASE MODEL; DRUG EFFECTS; LEWIS RAT; METABOLISM; MYELIN SHEATH; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; LACTOCOCCUS LACTIS; MULTIPLE SCLEROSIS; MYELIN SHEATH; RATS, INBRED LEW; SPINAL CORD;

EID: 84989818085     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: 10.5114/fn.2016.62534     Document Type: Article

References (42)

1. Abott JD, Blanchfield JL, Martinson DA, Russel SC, Taslim N, Curtis AD, Mannie MD. Neuroantigen-specific, tolerogenic vaccines: GM-CSF is a fusion partner that facilitates tolerance rather than immunity to domminant self-epitopes of myelin in murine models of experimental autoimmune encephalomyelitis (EAE). BMC Immunol 2011; 12: 72.
2. Adelmann M, Wood J, Benzel I, Fiori P, Lassman H, Matthieu JM, Gardinier MV, Dornmair K, Linington C. The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyalinating experimental autoimmune encephalomye litis in the Lewis rats. J Neuroimmunol 1995; 63: 17-27.
3. Axtell RC, de Jong BA, Boniface K, van der Voort L F, Bhat R, De Sarno P, Han M, Zhong F, Castellanos JG, Mair R, Christakos A, Kolkowitz I, Katz L, Killestein J, Polman CH, de Waal Malefyt R, Steinman L, Raman C. T helper type 1 and 17 cells determine efficacy of IFN-β in multiple sclerosis and experimental autoimmune encephalomyelitis. Nat Med 2010; 16: 406-412.
4. Benson JM, Campbell KA, Guan Z, Gienapp IE, Stuskman SS, Forsthuber T, Whitacre CC. T-cell activation and receptor downmodulation precede deletion induced by mucosally administered antigen. J Clin Invest 2000; 106: 1031-1038.
5. Bermudez-Humaran LG. Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins. Hum Vaccin 2009; 5: 264-267.
6. Bermudez-Humaran LG, Nouaille S, Zilberfarb V, Corthier G, Cruss A, Langella P, Issad T. Effects of intranasal administration of a leptin-secreting Lactococcus lactis recombinant on food intake, body weight, and immune response of mice. Appl Environ Microbiol 2007; 73: 5300-5307.
7. Bielekova B, Richert N, Blevins G, Markovic-Plese S, McCartin J, Frank JA, Würfel J, Ohayon J, Waldmann TA, McFarland H F, Martin R. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β. Proc Natl Acad Sci U S A 2004; 101: 8705-8708.
8. Castro-Borrero W, Graves D, Frohman TC, Bates Flores A, Hardeman P, Logan D, Orchard M, Greenberg B, Frohman EM. Current and emerging therapies in multiple sclerosis: a systemic review. Ther Adv Neurol Disord 2012; 5: 205-220.
9. Coles AJ Alemtezumab therapy for multiple sclerosis. Neurotherapeutics 2013; 1: 29-33.
10. Dąbrowska-Bouta B, Stróżyńska L, Chalimoniuk M, Frontczak-Baniewicz M, Sulkowski G. The influence of glutamatergic receptor antagonists on biochemical and ultrastructural changes in myelin membranes of rats subjected to experimental autoimmune encephalomyelitis. Folia Neuropathol 2015; 53: 317-326.
11. Faria AMC, Weiner HL. Oral tolerance: implications for autoimmune diseases. Clin Dev Immunol 2006; 13: 143-157.
12. Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KHG T cells in multiple sclerosis and experimental allergic encephalomyelitis. Clin Exp Immunol 2010; 162: 1-11.
13. Franklin RJ, Ffrench-Constant C, Edgar JM, Smith KJ. Neuroprotection and repair in multiple sclerosis. Nature reviews. Neurology 2012; 8: 624-634.
14. Hara H, Nanri Y, Tabata E, Mitsutake S, Tabira T. Identification of astrocyte-derived immune suppressor factor that induces apoptosis of autoreactive T cells. J Neuroimmunol 2011; 233: 135-146.
15. Higgins PJ, Weiner HL Supression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J Immunol 1988; 140: 440-445.
16. Huibregste IL, Snoeck V, de Creus A, Braat H, De Jong EC, Van Deventer SJ, Rottiers P. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin. Gastroenterology 2007; 133: 517-528.
17. Jurynczyk M, Walczak A, Jurewicz A, Jesionek-Kupnicka D, Szczepanik M, Selmaj K. Immune regulation of multiple sclerosis by transdermally applied myelin peptides. Ann Neurol 2010; 68: 593-601.
18. Kasarello K, Gadamski R, Piotrowski P, Kurzepa K, Kwiatkowska-Patzer B, Lipkowski AW. Effect of oral administration of pig spinal cord hydrolysate on clinical and histopathological symptoms of experimental allergic encephalomyelitis in rats. Folia Neuropathol 2015; 53: 128-138.
19. Kasarello K, Kwiatkowska-Patzer B, Lipkowski AW, Bardowski JK, Szczepankowska AK. Oral administration of Lactococcus lactis expressing synthetic genes of myelin antigens in decreasing experimental autoimmune encephalomyelitis in rats. Med Sci Monit 2015; 21: 1587-1597.
20. Lalor SJ, Dungan LS, Sutton CE, Basedo SA, Fletcher JM, Mills KH. Caspase-1-processed cytokines IL-1β and IL-18 promote IL-17 production by γδ and CD4 T cells that mediate autoimmmunity J Immunol 2013; 186: 5738-5748.
21. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nature Reviews. Neurology 2012; 8: 647-656.
22. Lavasani S, Dzhambazov B, Nouri MA, Fak F, Buske S, Molin G, Thorlacius H, Alenfall J, Jeppsson B, Weström B. A novel probiotic mixture exerts a therapeutic effect on expreimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS One 2010; 5: 1-11.
23. Link H, Xiao BG. Rat models as tool to develop new immunotherapies. Immunol Rev 2001; 184: 117-128.
24. Lyck R, Engelhardt B. Going Against the tide - how encephalogenic T cells breach the blood-brain barrier. J Vasc Res 2001; 49: 4497-4509.
25. Maillard MH, Snapper SB. Teaching tolerance with a probiotic antigen delivery system. Gastroenterology 2007; 133: 706-709.
26. Meyer AL, Benson JM, Giennap IE, Cox KL, Whitacre CC. Supression of murine chronic relapsing experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. J Immunol 1996; 157: 4230-4238.
27. Mirenda V, Millington O, Lechler RI, Scott D, Hernandez-Fuentes MP, Read J, Tan PH, George AJT, Garside P, Marelli-Gerg FM. Tolerant T cells display impaired trafficking ability. Eur J Immunol 2005; 35: 2146-2156.
28. Morello E, Bermudez-Humaran LG, Llull D, Sole V, Miraglio N, Langella P, Poquet I. Lactococcus lactis, an efficient cell factory for recombinant protein production and secretion. J Mol Microbol Biotechnol 2008; 14: 48-58.
29. Pabst O, Mowat AM. Oral tolerance to food protein. Mucosal Immunol 2012; 5: 232-239.
30. Reynolds R, Roncaroli F, Nicholas R, Radotra B, Gveric D, Howell O. The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathol 2011; 122: 155-170.
31. Rodgers JM, Miller SD. Cytokine control of inflammation and repair in the pathology of multiple sclerosis. Yale J Biol Med 2012; 85: 447-468.
32. Sanvito L, Constantinescu CS, Gran B, 't Hart BA. The Multifaceted Role of Interferon-γ in Central Nervous System Autoimmune Demyelination. The Open Autoimmunity Journal 2010; 2: 151-159.
33. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991; 325: 467-472.
34. Song F, Wardrop RM, Giennap IE, Stuckman SS, Meyer AL, Shawler T, Whitacre CC. The Peyer's patch is a critical immunoregulatory site for mucosal tolerance in experimental autoimmune encephalomyelitis (EAE). J Autoimmun 2008; 30: 230-237.
35. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747.
36. Terzaghi BE, Sandine WE. Improved medium for lactic streptococci and their bacteriophages. Appl Microbiol 1975; 29: 807-813.
37. Wardrop RM, Whitacre CC. Oral tolerance in the treatment of inflammatory autoimmune diseases. Inflamm Res 1999; 48: 106-119.
38. Weiner HL Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997; 18: 335-343.
39. Wekerle H, Kurschus FC. Animal models for multiple sclerosis. Drug Discov Today: Disease Models 2006; 3: 359-367.
40. Wells JM, Rossi O, Meijerink M, Baarlen van P. Epithelial crosstalk at the microbiota-mucosal interface. Proc Natl Acad Sci U S A 2011; 108: 4607-4614.
41. Whitacre CC, Gienapp IE, Orosz CG, Bitar DM. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. J Immunol 1991; 147: 2155-2163.
42. Ziemssen T, Ziemmssen F. The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental allergic encephalomyelitis (EAE). Autoimmun Rev 2010; 4: 460-467.